Tasosartan

Tasosartan
Clinical data
Pregnancy; category	N/A;
ATC code	C09CA05 (WHO) ;
Legal status
Legal status	Withdrawn;
Identifiers
	IUPAC name 2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one;
CAS Number	145733-36-4 ;
PubChem CID	60919;
IUPHAR/BPS	6898;
DrugBank	DB01349 ;
ChemSpider	54890 ;
UNII	48G92V856H;
CompTox Dashboard (EPA)	DTXSID40163148 ;
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
	(what is this?) (verify)

Tasosartan is an

angiotensin II receptor antagonist

.

It was withdrawn from FDA review by the manufacturer after

phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.^[1]^[2]

References

ISBN 978-0-12-369417-1
.

PMID 10902066
.

v
t
e
Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors
("-pril")

Sulfhydryl-containing: Captopril

Rentiapril

Zofenopril

Dicarboxylate-containing: Enalapril^#

Benazepril

Cilazapril

Delapril

Imidapril

Lisinopril (+amlodipine, +HCT)

Moexipril

Perindopril (+indapamide)

+HCT
)

Ramipril

Spirapril

Temocapril

Trandolapril

Phosphonate-containing: Ceronapril

+HCT
)

Other/ungrouped: Alacepril

AIIRAs

("-sartan")

Azilsartan

Candesartan

Eprosartan

Fimasartan

+HCT
)

Losartan (+HCT)

Olmesartan (+amlodipine, +amlodipine and HCT, +HCT)

Tasosartan^§

Telmisartan (+amlodipine, +HCT)

+amlodipine and HCT, +HCT, +nebivolol
)

Renin inhibitors
("-kiren")

Aliskiren (+amlodipine, +HCT, +amlodipine and HCT)

Remikiren^§

Dual ACE/NEP inhibitors

Gemopatrilat

Ilepatril

Omapatrilat

Sampatrilat

Neprilysin inhibitors

Sacubitril (+valsartan)

^#WHO-EM

^‡Withdrawn from market

Clinical trials:
^†Phase III

^§Never to phase III

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tasosartan&oldid=1076207952"

[1] ISBN 978-0-12-369417-1
.

[2] PMID 10902066
.

[1]

[2]